产品货号

CP132

产品规格

1/5/25/50/100mg

反应种属

Mouse

克隆号

DC101-CP132

同种型

Mouse   IgG2a(switched from rat IgG1)

免疫原

Mouse   VEGFR-2-SEAPs soluble receptor

实验应用

in   vivo blocking of VEGF/VEGFR-2 signaling*
  in vitro blocking of VEGFR signaling*
  Western blot*
  *Reported for the original rat IgG1 DC101 antibody

产品形式

PBS, pH   7.0,Contains no stabilizers or preservatives

纯度

>95%,   Determined by SDS-PAGE

聚合

<5%,   Determined by SEC

无菌处理

0.2 µm   filtration

纯化方式

Protein G

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox   Virus: Negative

Hantavirus:   Negative

K Virus:   Negative

Lactate   Dehydrogenase-Elevating Virus: Negative

Lymphocytic   Choriomeningitis virus: Negative

Mouse   Adenovirus: Negative

Mouse   Cytomegalovirus: Negative

Mouse   Hepatitis Virus: Negative

Mouse Minute   Virus: Negative

Mouse   Norovirus: Negative

Mouse   Parvovirus: Negative

Mouse   Rotavirus: Negative

Mycoplasma   Pulmonis: Negative

Pneumonia   Virus of Mice: Negative

Polyoma   Virus: Negative

Reovirus   Screen: Negative

Sendai   Virus: Negative

Theiler’s   Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C，不能冷冻保存。

推荐同型对照

InVivoPlus   mouse IgG2a isotype control, unknown specificity（货号BP0085）

推荐抗体稀释液

InVivoPure   pH 7.0 Dilution Buffer（货号IP0070）

体内VEGF/VEGFR-2信号阻断

(in vivo   blocking of VEGF/VEGFR-2 signaling)

1. Ding,   X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived   VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.

2. Lee,   H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and   hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma   mouse models through destruction of tumor vasculature' Int J Radiat Oncol   Biol Phys 91(3): 621-630.

3. Arulanandam,   R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression   Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2):   210-224.

4. Kizhatil,   K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of   blood vascular and lymphatic phenotypes that forms by a novel developmental   process' PLoS Biol 12(7): e1001912.

体内VEGF/VEGFR-2信号阻断，体外VEGFR信号阻断

(in vivo   blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling)

1.Larrayoz,   M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to   antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4):   539-550.